Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 3/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31552249 | 0.86 | IMPDH2 (0.61) | IMPDH2ERN1KDM4EMAPKAPK2L3MBTL1 | |
| SCHEMBL1705034 | 0.86 | IMPDH2 (0.61) | IMPDH2ERN1KDM4EMAPKAPK2L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL30343227 | 0.73 | L3MBTL1 (0.42) | IMPDH2SLC22A12KDM4EL3MBTL1 | |
| SCHEMBL3711409 | 0.70 | KDM4E (0.41) | IMPDH2ERN1TRPV1KDM4EMAPKAPK2 | |
| Trifluoroacetic Acid SCHEMBL1655915 | 0.70 | CSNK2A1 (0.38) | IMPDH2ERN1TRPV1SLC22A12CSNK2A2 | |
| Isoquinoline SCHEMBL4339110 | 0.69 | IMPDH2 (0.46) | IMPDH2TRPV1SLC22A12L3MBTL1 | |
| Isoquinoline SCHEMBL27990251 | 0.69 | IMPDH2 (0.46) | IMPDH2TRPV1SLC22A12L3MBTL1 | |
| Isoquinoline SCHEMBL4339108 | 0.69 | IMPDH2 (0.46) | IMPDH2TRPV1SLC22A12L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL1655913 | 0.69 | CDK2 (0.36) | IMPDH2ERN1TRPV1SLC22A12CSNK2A2 | |
| SCHEMBL1706043 | 0.69 | IMPDH2 (0.61) | IMPDH2ERN1KDM4EMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796458-B2 | Cyclohexylamine isoquinolone derivatives | SANOFI (FR) | 2014-08-05 | — | — | US | disclosed |
| US-8722671-B2 | Isoquinoline derivatives | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8609691-B2 | Cyclohexylamin isoquinolone derivatives | SANOFI (FR) | 2013-12-17 | — | — | US | disclosed |
| US-8501736-B2 | Isoquinoline derivatives | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-20110251226-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| US-20110245248-A1 | ISOQUINOLINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | disclosed |
| EP-1912949-B1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI SA (FR) | 2011-08-24 | — | — | EP | disclosed |
| EP-1899322-B1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI AVENTIS (FR) | 2009-09-02 | — | — | EP | disclosed |
| US-20090088429-A1 | Isoquinoline Derivatives | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | US | disclosed |
| US-20080242699-A1 | Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase inhibitors; Hypotensive agents; 6-(4-Amino-cyclohexyloxy)-2-(4-methoxy-benzyl)-7-propyl-2H-isoquinolin-1-one | SANOFI-AVENTIS (FR) | 2008-10-02 | — | — | US | disclosed |
| EP-1912949-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | Sanofi-Aventis (FR) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007012422-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242699-A1 | Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase inhibitors; Hypotensive agents; 6-(4-Amino-cyclohexyloxy)-2-(4-methoxy-benzyl)-7-propyl-2H-isoquinolin-1-one | MYLK, MYLK2, ROCK1 | IMPDH2 1221/4885ERN1 1897/4885TRPV1 3209/4885 |
| US-20110245248-A1 | ISOQUINOLINE DERIVATIVES | MYLK2, MYLK, RHOT2 | IMPDH2 897/4885ERN1 2404/4885TRPV1 4354/4885 |
| US-20110251226-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES | MYLK2, MYLK, MYLK3 | IMPDH2 386/4885ERN1 2539/4885TRPV1 4598/4885 |
| US-20090088429-A1 | Isoquinoline Derivatives | MYLK2, MYLK, RHOT2 | IMPDH2 897/4885ERN1 2404/4885TRPV1 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.